CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
11.00
-0.27 (-2.40%)
At close: Oct 9, 2025, 4:00 PM EDT
11.10
+0.10 (0.91%)
After-hours: Oct 9, 2025, 7:58 PM EDT
CorMedix Revenue
CorMedix had revenue of $39.74M in the quarter ending June 30, 2025, with 4,829.40% growth. This brings the company's revenue in the last twelve months to $121.48M, up 14,970.29% year-over-year. In the year 2024, CorMedix had annual revenue of $43.47M.
Revenue (ttm)
$121.48M
Revenue Growth
+14,970.29%
P/S Ratio
5.74
Revenue / Employee
$1,868,992
Employees
65
Market Cap
858.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43.47M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
| Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
| Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CRMD News
- 10 days ago - CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO - GlobeNewsWire
- 17 days ago - CorMedix: Strong Adoption Curve And Policy Environment - Seeking Alpha
- 4 weeks ago - CorMedix Inc. (CRMD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - CorMedix Announces Strategic Minority Investment in Talphera - GlobeNewsWire
- 4 weeks ago - Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market - PRNewsWire
- 5 weeks ago - CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team - GlobeNewsWire
- 6 weeks ago - CorMedix to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - CorMedix: The Undervalued Breakthrough - Seeking Alpha